← Eichor
Study identifier: NCT06557369 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD

Condition: Intermediate AMD  ·  Sponsor: Oculox Technologies SA

PhaseNA
Planned participants30
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect. By combining two clinically standard laser-light treatment, both exhibiting a solid-safe profile: the photothermal and the photobiological techniques; the investigational device (reSEES) wants to explore a completely new therapeutic approach by synergically take advantage of the inherent and already observed clinical performances of the two independent techniques.

This description comes directly from the study's public registry record.

Talk to the study team

Mario Romano, Prof.  ·  +39 02 8224 2555  ·  mario.romano.md@gmail.com

Maria Belotti, MD  ·  +39 02 8224 2555  ·  maria.belotti@gavazzeni.it

Always discuss trial participation with your own doctor first.

Locations (1)

Humanitas CastelliBergamo, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06557369